Digital Disruptors

January 7, 2019 James Linnington

Digital Disruptors - Disrupting Drug Development

2017 was the year where pharma realized that Big Data approaches could dramatically increase the value of data produced during drug development.

2018 was the year where it became clear that AI technologies (Machine Learning, Natural Language Understanding, BOT automation, Image Processing) were needed to unlock the full value of Big Data.

2019 is the year where we have everything in our hands to drive digital transformation; it will be the year that will differentiate the laggards and the leaders, providing competitive advantage to forward-thinking organizations. Leaders will “disrupt” current processes with digital technologies and reverse the current trend – drug development timelines of 12 years on average – and bring much-needed therapies to the market sooner.

But what do we mean by digital technologies? What are they? How can they disrupt drug development? What are the implications for regulators; how will they approve usage of sensors, BOTs, AI/ Machine Learning, and Blockchain. Do Pharma and regulators need to rethink their organization to embrace these new technologies effectively?  And will the patients accept this digital transformation; will it increase their adherence to trials and treatment, and prepare a natural continuum with mHealth?

At DIA Europe Vienna in February, I have the pleasure to co-chair the Digital Disruptors theme where we have 7 exciting sessions that will concentrate on understanding what we mean by digital disruptors – including a very interesting session on Blockchain. We will explore how regulator view them, what will be the impact on trial execution, how patients will accept these technologies, and finally what are the new European initiatives in IMI around mHealth.

I will initiate the theme starting with a DIAmond session – where top leaders from regulatory, pharmaceutical and patient organizations will share their view how digitization and new technologies may introduce a paradigm shift in drug development.

Please join us next month in Vienna at DIA Europe, where I will be joined by other PAREXEL's Peter Shone and Julia Lakeland to discuss these emerging technologies and how to embrace them to successfully transform the way we care for patients.

 

Isabelle de Zegher

VP, Integrated Solutions

PAREXEL

Isabelle de Zegher

 

                                                                        

Previous Item
How to Take the Lead in Reinventing the Life Sciences Industry
How to Take the Lead in Reinventing the Life Sciences Industry

Next Item
Machine Learning and Predictive Analytics Applications in Clinical Data Management
Machine Learning and Predictive Analytics Applications in Clinical Data Management